Analysts Set Immatics N.V. (NASDAQ:IMTX) PT at $13.67

Immatics N.V. (NASDAQ:IMTX) has received an average rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $15.00.

A number of equities analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Immatics in a research note on Wednesday, October 8th. Zacks Research raised shares of Immatics from a “strong sell” rating to a “hold” rating in a report on Monday, October 13th. Guggenheim started coverage on Immatics in a research report on Thursday, September 18th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Mizuho set a $19.00 price objective on Immatics in a research note on Wednesday.

Immatics Price Performance

NASDAQ:IMTX opened at $10.34 on Friday. The company has a market cap of $1.26 billion, a price-to-earnings ratio of -15.91 and a beta of 1.22. Immatics has a 1 year low of $3.30 and a 1 year high of $11.25. The stock’s 50 day simple moving average is $7.80 and its two-hundred day simple moving average is $6.33.

Immatics (NASDAQ:IMTX) last posted its earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.28). Immatics had a negative net margin of 59.29% and a negative return on equity of 15.60%. The business had revenue of $6.48 million during the quarter, compared to analysts’ expectations of $13.05 million. As a group, analysts anticipate that Immatics will post -0.72 EPS for the current year.

Institutional Trading of Immatics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE lifted its position in Immatics by 166.0% in the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after buying an additional 2,231 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in shares of Immatics in the second quarter valued at $59,000. Engineers Gate Manager LP bought a new stake in shares of Immatics in the 2nd quarter worth about $124,000. Fox Run Management L.L.C. bought a new stake in shares of Immatics in the 2nd quarter worth about $136,000. Finally, Pale Fire Capital SE boosted its stake in shares of Immatics by 8.9% during the 1st quarter. Pale Fire Capital SE now owns 34,270 shares of the company’s stock worth $155,000 after purchasing an additional 2,808 shares during the period. Hedge funds and other institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.